Georgia Institute of Technology and Emory University researchers created a new artificial intelligence-based tool to assist clinicians in predicting which symptoms COVID-19 patients will experience based on comorbidities. Additionally, the AI tool can suggest specific FDA-approved drugs for treatment.
The new tool is called MOATAI-VIR (Mode Of Action proteins & Targeted therapeutic discovery driven by Artificial Intelligence for VIRuses.) According to researchers, the artificial intelligence tool predicts 24 out of 26 major clinical manifestations of COVID-19 and the underlying disease-protein-pathway relationships.
The clinical manifestations include a range of side effects such as acute respiratory distress, blood clotting issues, cytokine storms, low blood oxygen levels, low white blood cell counts, and marrow failure. Other more common symptoms, including loss of smell or taste and “brain fog,” were also examined.
Le règlement DORA : un tournant majeur pour la cybersécurité des institutions financières Le 17…
L’Agence nationale de la sécurité des systèmes d'information (ANSSI) a publié un rapport sur les…
Directive NIS 2 : Comprendre les nouvelles obligations en cybersécurité pour les entreprises européennes La…
Alors que la directive européenne NIS 2 s’apprête à transformer en profondeur la gouvernance de…
L'intelligence artificielle (IA) révolutionne le paysage de la cybersécurité, mais pas toujours dans le bon…
Des chercheurs en cybersécurité ont détecté une intensification des activités du groupe APT36, affilié au…
This website uses cookies.